drugset
drugset / Trial / NCT05274191

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

NCT05274191 ↗

Phase 2 Unknown 60 enrolled Zhongshan Hospital Xiamen University
NaSingle-groupOpen-labelTreatment

Summary

A single arm, open-label Phase II clinical study.The subjects were patients with lung, gastric and colorectal cancers.

Timeline

Start
2022-03-04
Primary completion
2022-03-15
Completion
2024-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Pyrotinib Small molecule 400 mg Oral

Indications

cancer